The Estimated Lifetime Medical Cost of Chlamydia, Gonorrhea, and Trichomoniasis in the United States, 2018.
Journal
Sexually transmitted diseases
ISSN: 1537-4521
Titre abrégé: Sex Transm Dis
Pays: United States
ID NLM: 7705941
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
pubmed:
26
1
2021
medline:
25
5
2021
entrez:
25
1
2021
Statut:
ppublish
Résumé
The purpose of this study was to provide updated estimates of the average lifetime medical cost per infection for chlamydia, gonorrhea, and trichomoniasis. We adapted a published decision tree model that allowed for 7 possible outcomes of infection: (1) symptomatic infection, treated, no sequelae; (2) symptomatic infection, not treated, sequelae; (3) symptomatic infection, not treated, no sequelae; (4) asymptomatic infection, treated, sequelae; (5) asymptomatic infection, treated, no sequelae; (6) asymptomatic infection, not treated, sequelae; and (7) asymptomatic infection, not treated, no sequelae. The base case values and ranges we applied for the model inputs (i.e., the probability and cost assumptions) were based on published studies. The estimated lifetime medical costs per infection for men and women, respectively, were $46 (95% credibility interval, $32-$62) and $262 ($127-$483) for chlamydia, $78 ($36-$145) and $254 ($96-$518) for gonorrhea, and $5 ($1-$14) and $36 ($17-$58) for trichomoniasis. Cost estimates for men were most sensitive to assumptions regarding the probability that the infection is symptomatic, the probability of treatment if asymptomatic, and the cost of treatment of infection. Cost estimates for chlamydia and gonorrhea in women were most sensitive to assumptions regarding the probability and cost of subsequent pelvic inflammatory disease. These estimates of the lifetime medical cost per infection can inform updated estimates of the total annual cost of sexually transmitted infections in the United States, as well as analyses of the value and cost-effectiveness of sexually transmitted infection prevention interventions.
Sections du résumé
BACKGROUND
The purpose of this study was to provide updated estimates of the average lifetime medical cost per infection for chlamydia, gonorrhea, and trichomoniasis.
METHODS
We adapted a published decision tree model that allowed for 7 possible outcomes of infection: (1) symptomatic infection, treated, no sequelae; (2) symptomatic infection, not treated, sequelae; (3) symptomatic infection, not treated, no sequelae; (4) asymptomatic infection, treated, sequelae; (5) asymptomatic infection, treated, no sequelae; (6) asymptomatic infection, not treated, sequelae; and (7) asymptomatic infection, not treated, no sequelae. The base case values and ranges we applied for the model inputs (i.e., the probability and cost assumptions) were based on published studies.
RESULTS
The estimated lifetime medical costs per infection for men and women, respectively, were $46 (95% credibility interval, $32-$62) and $262 ($127-$483) for chlamydia, $78 ($36-$145) and $254 ($96-$518) for gonorrhea, and $5 ($1-$14) and $36 ($17-$58) for trichomoniasis. Cost estimates for men were most sensitive to assumptions regarding the probability that the infection is symptomatic, the probability of treatment if asymptomatic, and the cost of treatment of infection. Cost estimates for chlamydia and gonorrhea in women were most sensitive to assumptions regarding the probability and cost of subsequent pelvic inflammatory disease.
CONCLUSIONS
These estimates of the lifetime medical cost per infection can inform updated estimates of the total annual cost of sexually transmitted infections in the United States, as well as analyses of the value and cost-effectiveness of sexually transmitted infection prevention interventions.
Identifiants
pubmed: 33492090
doi: 10.1097/OLQ.0000000000001357
pii: 00007435-202104000-00006
pmc: PMC10440745
mid: NIHMS1919607
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
238-246Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2021 American Sexually Transmitted Diseases Association. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of Interest and Sources of Funding: None declared.
Références
Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2018. Atlanta, GA: U.S. Department of Health and Human Services:2019.
Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64(RR-03):1–137.
Owusu-Edusei K Jr., Chesson HW, Gift TL, et al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis 2013; 40:197–201.
Magid D, Douglas JM Jr., Schwartz JS. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: An incremental cost-effectiveness analysis. Ann Intern Med 1996; 124:389–399.
Oakeshott P, Kerry S, Aghaizu A, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: The POPI (Prevention of Pelvic Infection) trial. BMJ 2010; 340:c1642.
Price MJ, Ades AE, De Angelis D, et al. Risk of pelvic inflammatory disease following Chlamydia trachomatis infection: Analysis of prospective studies with a multistate model. Am J Epidemiol 2013; 178:484–492.
Kumar S, Chesson H, Gift TL. Estimating the direct medical costs and productivity loss of outpatient chlamydia and gonorrhea treatment. Sex Transm Dis 2021; 48:e18–e21.
Kumar S, Chesson H, Gift TL. Estimating the direct medical outpatient costs of diagnosis and treatment of trichomoniasis among commercially insured patients in the United States, 2016 to 2018. Sex Transm Dis 2021;48:e45–e47.
Dean LT, Montgomery MC, Raifman J, et al. The affordability of providing sexually transmitted disease services at a safety-net clinic. Am J Prev Med 2018; 54:552–558.
Gift TL, Owens CJ. The direct medical cost of epididymitis and orchitis: Evidence from a study of insurance claims. Sex Transm Dis 2006; 33(10 Suppl):S84–S88.
Rein DB, Gift TL. A refined estimate of the lifetime cost of pelvic inflammatory disease. Sex Transm Dis 2004; 31:325.
Kreisel KM, Weston EJ, St. Cyr SB, Spicknall IH. Estimates of the prevalence and incidence of chlamydia and gonorrhea among US men and women, 2018. Sex Transm Dis 2021; 48:222–231.
Lewis FMT, Spicknall IH, Flagg EW, Papp JR, Kreisel KM. Incidence and prevalence of Trichomonas vaginalis infection among persons aged 15–59: United States, 2018. Sex Transm Dis 2021; 48:232–237.
Rein DB, Kassler WJ, Irwin KL, et al. Direct medical cost of pelvic inflammatory disease and its sequelae: Decreasing, but still substantial. Obstet Gynecol 2000; 95:397–402.
Trent M, Ellen JM, Frick KD. Estimating the direct costs of pelvic inflammatory disease in adolescents: A within-system analysis. Sex Transm Dis 2011; 38:326–328.
Institute of Medicine. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: National Academy of Sciences, 2000.
Ong KJ, Soldan K, Jit M, et al. Chlamydia sequelae cost estimates used in current economic evaluations: Does one-size-fit-all?Sex Transm Infect 2017; 93:18–24.
Trussell J, Henry N, Hassan F, et al. Burden of unintended pregnancy in the United States: Potential savings with increased use of long-acting reversible contraception. Contraception 2013; 87:154–161.
Canestaro W, Vodicka E, Downing D, et al. Implications of employer coverage of contraception: Cost-effectiveness analysis of contraception coverage under an employer mandate. Contraception 2017; 95:77–89.
Katz P, Showstack J, Smith JF, et al. Costs of infertility treatment: Results from an 18-month prospective cohort study. Fertil Steril 2011; 95:915–921.
Boulet SL, Kawwass J, Session D, et al. US state-level infertility insurance mandates and health plan expenditures on infertility treatments. Matern Child Health J 2019; 23:623–632.
Yeh JM, Hook EW 3rd, Goldie SJ. A refined estimate of the average lifetime cost of pelvic inflammatory disease. Sex Transm Dis 2003; 30:369–378.
Huntington SE, Burns RM, Harding-Esch E, et al. Modelling-based evaluation of the costs, benefits and cost-effectiveness of multipathogen point-of-care tests for sexually transmitted infections in symptomatic genitourinary medicine clinic attendees. BMJ Open 2018; 8:e020394.
Neumann PJ, Sanders GD, Russell LB, et al. Cost-Effectiveness in Health and Medicine. 2nd ed. New York, NY: Oxford University Press, 2016.
Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010; 28:6858–6867.
Kreisel KM, Spicknall IH, Gargano JW, et al. Sexually transmitted infections among US women and men: Prevalence and incidence estimates, 2018. Sex Transm Dis 2021; 48:208–214.
Jichlinski A, Badolato G, Pastor W, et al. HIV and syphilis screening among adolescents diagnosed with pelvic inflammatory disease. Pediatrics 2018; 142:e20174061.
Trent M. Status of adolescent pelvic inflammatory disease management in the United States. Curr Opin Obstet Gynecol 2013; 25:350–356.
Mitchell C, Prabhu M. Pelvic inflammatory disease: Current concepts in pathogenesis, diagnosis and treatment. Infect Dis Clin North Am 2013; 27:793–809.
Price MJ, Ades AE, Welton NJ, et al. Proportion of pelvic inflammatory disease cases caused by Chlamydia trachomatis : Consistent picture from different methods. J Infect Dis 2016; 214:617–624.
Mitchell C. To effectively treat pelvic inflammatory disease, look beyond coverage for gonorrhea and chlamydia. Clin Inf Dis, published ahead of print .
Tao G. Trend in rates of pelvic inflammatory disease diagnosed among commercially-insured women aged 15-44 years in the United States, 2009-2017. 2020 STD Prevention Conference. September 14-24, 2020; [Conference held virtually].
Kreisel K, Torrone E, Bernstein K, et al. Prevalence of pelvic inflammatory disease in sexually experienced women of reproductive age - United States, 2013-2014. MMWR Morb Mortal Wkly Rep. 2017; 66:80–83.
Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates. 2008. Sex Transm Dis 2013; 40:187–193.
Lisonkova S, Tan J, Wen Q, et al. Temporal trends in severe morbidity and mortality associated with ectopic pregnancy requiring hospitalisation in Washington State, USA: a population-based study. BMJ Open 2019; 9:e024353.
Hoover KW, Tao G, Kent CK. Trends in the diagnosis and treatment of ectopic pregnancy in the United States. Obstet Gynecol 2010; 115:495–502.
Owusu-Edusei K Jr., Gift TL, Chesson HW. Treatment cost of acute gonococcal infections: estimates from employer-sponsored private insurance claims data in the United States, 2003-2007. Sex Transm Dis 2010; 37:316–318.
Curry A, Williams T, Penny ML. Pelvic inflammatory disease: diagnosis, management. and prevention. Am Fam Physician 2019; 100:357–364.
Brunham RC, Gottlieb SL, Paavonen J. Pelvic inflammatory disease. New Eng J Med 2015; 372:2039–2048.
Reekie J, Donovan B, Guy R, et al. Risk of pelvic inflammatory disease in relation to chlamydia and gonorrhea testing, repeat testing, and positivity: a population-based cohort study. Clin Inf Dis 2018; 66:437–443.
Hillis SD, Owens LM, Marchbanks PA, et al. Recurrent chlamydial infections increase the risks of hospitalization for ectopic pregnancy and pelvic inflammatory disease. Am J Obstet Gynecol 1997; 176(1 Pt 1):103–107.
Bautista CT, Hollingsworth BP, Sanchez JL. Repeat chlamydia diagnoses increase the hazard of pelvic inflammatory disease among us army women: a retrospective cohort analysis. Sex Transm Dis 2018; 45:770–773.
Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Dis 1999; 75:3–17.
Chesson H, Song R, Bingham A, et al. The estimated number and lifetime medical cost of HIV infections attributable to sexually transmitted infections acquired in the United States in 2018: A compilation of published modeling results. Sex Transm Dis 2021; 48:292–298.
Chesson HW, Spicknall IH, Bingham A, et al. The estimated direct lifetime medical costs of sexually transmitted infections acquired in the United States in 2018. Sex Transm Dis 2021; 48:215–221.
Howell MR, Quinn TC, Gaydos CA. Screening for Chlamydia trachomatis in asymptomatic women attending family planning clinics. A cost-effectiveness analysis of three strategies. Ann Intern Med 1998; 128:277–284.
Muzny CA, Kissinger P. Trichomonas vaginalis Infections. In: Bachmann L, ed. Sexually Transmitted Infections in HIV-Infected Adults and Special Populations. Cham: Springer, 2017:125–140.
Mielczarek E, Blaszkowska J. Trichomonas vaginalis: pathogenicity and potential role in human reproductive failure. Infection 2016; 44:447–458.
Wiringa AE, Ness RB, Darville T, et al. Trichomonas vaginalis, endometritis and sequelae among women with clinically suspected pelvic inflammatory disease. Sex Transm Inf 2020; 96:436–438.
Rönn MM, Tuite AR, Menzies NA, et al. The impact of screening and partner notification on chlamydia prevalence and numbers of infections averted in the United States, 2000-2015: evaluation of epidemiologic trends using a pair-formation transmission model. Am J Epidemiol 2019; 188:545–554.